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Appreciable phospholipase 4 activity was detected in a hind paw homogenate from rats with adjuvant arthritis or carrageenan-induced ema. 
The activity was neutralized by treatment with antibody raised against rat platelet secretory phospholipase 4, indicating that ICkDa group II 
phospholipase 4 was induced in the hind paw during the process of inflammation. Injection of purified rat platelet phospholipase A2 into the 
hind paw of rats with adjuvant-induced arthritis resulted in exacerbation of edema in a dose-dependent manner, whereas no effect was observed 
on either normal rats or animals with carrageenan-induced ema under the same experimental conditions. These results suggest he importance 
of mammalian group II phospholipase 4 in the pathogenesis of some types of inflammation. 
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1. INTRODUCTION 
Phospholipase A2 plays a central role in liberating 
free fatty acids and lysophospholipids from membrane 
phospholipids, thereby initiating the production of lipid 
mediators (eicosanoids, platelet activating factor, etc.) 
of the inflammatory process. Several studies have im- 
plicated extracellular phospholipases A2 in the 
pathogenesis of disorders of the cardiovascular, 
gastrointestinal and pulmonary systems, skin and con- 
nective tissues [ 11. Mammalian 14-kDa phospholipases 
AZ have been classified into two groups based on their 
primary structure [2]. Group I enzymes exist mainly in 
digestive organs such as the pancreas [3,4], while group 
II enzymes are widely distributed in non-pancreatic 
tissues such as the spleen [5,6], liver [7], intestine [8] or 
platelets [9-l 11. The group II enzymes have also been 
detected in exudated fluid at inflamed sites, such as 
glycogen-induced ascitic fluid in rabbits [12], casein- 
induced ascitic fluid in rats [13], or human synovial 
fluid in patients with rheumatoid arthritis [14-161. It is 
therefore postulated that group II phospholipase AZ 
may play some critical role in the process of inflamma- 
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tion. This idea has been further supported by observa- 
tions that inflammation was induced in animals by in- 
jection of phospholipases AZ [12-211. However, such 
induction of inflammation has not always been observ- 
ed, and sometimes no appreciable change has been 
detected at sites where purufied enzyme was injected. 
When a rat receives an intradermal injection of com- 
plete Freund’s adjuvant, chronic arthritis with 
remarkable paw edema develops, and this has been 
widely used as a model system for human rheumatoid 
arthritis. In the present study, we found that the levvel 
of phospholipase A2 was greatly elevated under these 
pathological conditions. Also, we observed that injec- 
tion of mammalian 16kDa group II phospholipase A2 
purified from rat platelets exacerbated the paw edema 
in rats with adjuvant arthritis. It is suggested that some 
pathological conditions may be required in order for 
the enzyme to become active. 
2. MATERIALS AND METHODS 
2.1. Adjuvant arthritis 
Male rats of the Sprague-Dawley (SD) strain, weighing 190-200 g 
(8 weeks old), were used. The adjuvant employed, a fine suspension 
of dry heat-killed Mycobacterium bufyricum (Difco) in light mineral 
oil (Bay01 F), was made up at a concentration of 10 mg/ml. Adjuvant 
arthritis was induced by an intradermal injection of 0.06 ml of adju- 
vant into the tail. Two weeks after the injection of adjuvant, rats 
showing medium to severe arthritis with remarkable dema (approx- 
imately 90% of total population) were selected and used [22]. 
2.2. Carrageenan-induced hind paw edema in rats 
Male SD rats, weighing 100-130 g, were used. Hind paw edema was 
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induced by subcutaneous injection of 0.1 ml of 1% carrageenan 
(Wako) solution into the right foot pad of rats [23]. 
2.3. Measurement of phospholipase AZ activity in hind paw 
homogenates 
Normal rats or those with inflammation were anesthetized with 
ether and killed. The hind paws of these rats were minced with 
scissors, suspended in 4 vol of 20 mM Tris-HCl (PH 7.4) containing 
1 mM EDTA relative to wet tissue weight, and homogenized in a 
Polytron homogenizer (Kinematica). Phospholipase AZ activity in the 
homogenates was measured using “C-labelled phosphatidylserine as 
a substrate, as described previously [24]. 
2.4. Measurement of phospholipase AZ content by sandwich ELISA 
Group II phospholipase A2 content in hind paw homogenates was 
determined by sandwich ELISA using solid-phase attached polyclonal 
antibody R377 and the soluble biotinylated monoclonal antibody 
MD7.1 as described previously [25]. Immunoaffinity-purified rat 
platelet phospholipase A2 was used as a standard. 
3. RESULTS 
The homogenates of hind paw obtained from normal 
rats, or those with adjuvant-induced arthritis or 
carrageenan-induced edema were tested for 
phospholipase A2 activity. Appreciable phospholipase 
A2 activity was detected in homogenates prepared from 
hind paws with both arthritis and carrageenan-induced 
paw edema, whereas the level of enzyme activity in the 
same parts of normal rat was very low (Fig. 1). When 
the homogenates were incubated with anti-rat 1CkDa 
group II phospholipase AZ antibody R377 [25], the 
phospholipase A2 activity was markedly reduced (Table 
I). The content of group II phospholipase AZ in the 
homogenates was determined immunochemically using 
a sandwich ELISA method developed previously (Table 
II). Approximately 1 pg of group II phospholipase A2 
was detected in the inflamed site of rat with adjuvant 
arthritis. The hind paw of rats with carrageenan- 
induced edema also contained a significantly high level 
of group II phospholipase AZ, although the content was 
relatively lower than that in adjuvant arthritis. It was 
thus concluded that mammalian 14-kDa group II 
phospholipase A2 is induced in both types of inflamma- 
tion. 
We next examined the effect of exogenous group II 
phospholipase AZ on the development of inflammation 
induced by either adjuvant-arthritic rats or rats with 
carrageenan-induced edema. To avoid the possibility 
that contaminating substances exerted biological ef- 
fects, we used the purest preparation so far available, 
an immunoaffinity-purified rat platelet phospholipase 
AZ, which gave a single protein band on SDS-PAGE 
followed by silver staining [25]. Injection of the 
phospholipase A2 into the hind paw of adjuvant- 
arthritic rats resulted in exacerbation of edema within 1 
h in a dose-dependent manner (Table III). The max- 
imum effect was observed at doses of over 2 pg of en- 
zyme. The effect lasted for at least 3 h, then decreased 
gradually, and disappeared 24 h after injection of the 
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Fig. 1. Phospholipase As activity in hind paw homogenates from nor- 
mal rats (A), rats with adjuvant arthritis (B) and rats with 
carrageenan-induced ema (C) (n = 6). The procedure is described in 
section 2. 
enzyme. On the other hand, no exacerbating effect was 
observed in either rats with carrageenan-induced ema 
or control rats even when 5 pg of phospholipase AZ was 
injected (Tables IV and V). 
Table I 
Effect of anti-rat 1CdKa group II phospholipase A2 antibody on 
phospholipase A2 activity in rat hind paw homogenates 






Phospholipase AZ activity 
(nmol) fatty acids 
released/min/ml 
0.63 + 0.20 
0.41 * 0.70 
5.04 f 0.56 
0.96 f 0.14 
3.45 f 1.17 
0.70 f 0.22 
Samples were incubated with 25 cg of antibody R377 [25] for 1 h on 
ice. The aliquots were then examined for phospholipase A2 activity. 
Each value is an average (& SE) of 3 independent samples. 
Table II 
Content of 14-kDa group II phospholipase A2 in hind paw 
homogenates determined by sandwich ELISA 
Sample n Content of 
phospholipase AZ 
(average (ng) f SE) 
Normal 6 not detectable 
Adjuvant 
arthritis 6 932.6 f 691.2 
Carrageenan- 
induced edema 6 136.8 f 34.1 
Content of phospholipase A2 was determined as described previously 
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Table III 
Effect of 14-kDa group II phospholipase AZ on adjuvant induced arthritis in rats 
Dose of phospholipase AZ Hind paw swelling 
OLg/paw) n (average (%‘o) f SE) 
1 3 6 24 h 
0 (untreated control) 6 0.8 f 1.8 4.3 f 1.6 3.2 f 1.3 6.2 + 2.1 
0 (vehicle control) 6 9.5 f 2.0 10.6 f 1.3 8.8 f 1.2 4.2 f 3.1 
0.2 6 11.4 + 4.3 11.7 f 5.0 1.8 f 4.3 - 1.1 f 1.8 
1 6 15.2 f 2.4 13.1 f 2.4 9.5 f 2.4 4.7 * 1.1 
2 6 18.4 k 2.4” 17.0 f 3.5 15.6 f 3.2 8.7 f 2.2 
5 6 16.6 f 2.2* 17.2 f 1.9* 14.5 f 1.6* 6.4 f 3.4 
Purified rat platelet phospholipase AZ was diluted with phosphate-buffered saline (PBS; pH 6.5) containing 0.1% gelatin and injected into the hind 
paw of rats with adjuvant arthritis (0.1 ml/paw). Hind paw volume was measured at indicated times after the injection of the enzyme by the water 
displacement method [22,23]. 
* 0.01~ P-co.05 significantly different from each vehicle group 
Table IV 
Effect of 1CkDa group II phospholipase A2 on carrageenan-induced hind paw edema in rats 
Dose of phospholipase A2 Hind paw swelling 
&g/paw) n (average (olo) f SE) 
1 2 3 4 5h 
0 (untreated control) 6 4.4 * 1.0* 1.4 + 0.8** -0.6 f 1.9: -4.5 f 2.1’ -8.3 f 2.1* 
0 (vehicle control) 6 8.3 f 1.0 6.9 f 0.6 6.3 f 0.5 2.9 + 0.7 -2.2 f 1.2 
2 6 7.1 * 0.7 7.2 + 0.8 5.5 f 1.2 1.1 * 1.3 -2.1 * 1.3 
5 6 6.2 f 0.7 4.9 f 0.8 3.1 + 0.9** -0.8 f 1.2* -5.8 * 0.9 
Two hours after injection of carrageenan, purified rat platelet phospholipase A2 in PBS (pH 6.5) containing 0.1% gelatin was injected into the 
hind paw of rats with edema (0.1 ml/paw). Hind paw volume was measured as described in Table III. 
* 0.01 <P<O.OS and ** P<O.Ol significantly different from each vehicle control group 
Table V 
Effect of 14-kDa group II phospholipase A2 on normal rats 
Dose of phospholipase A2 Hind paw swelling 
GLg/paw) n (average (%) f SE) 
1 2 3 4 5h 
0 (untreated control) 6 1.9 * 2.0** 0.4 f 1.3** -0.3 It 1.0** -3.7 + 1.2** -0.7 + 1.3** 
0 (vehicle control) 6 17.8 + 2.4 14.4 + 1.7 12.1 * 1.5 6.4 * 1.8 1.5 + 0.6 
5 6 15.2 f 0.9 8.1 + 1.4* 6.8 f 1.5* 1.3 f 1.4 -1.1 f 1.4 
Purified rat platelet phospholipase AZ in PBS (pH 6.5) containing 0.1% gelatin was injected into the hind paw of normal rats (0.1 ml/paw). Hind 
paw volume was measured as described in Table III. 
* 0.01 < P<O.O5 and ** P<O.Ol significantly different from each vehicle control group 
4. DISCUSSION 
Adjuvant arthritis in rats is characterized as a form of 
chronic inflammation mediated by cellular immunity 
[26], whereas carrageenan-induced edema is an acute 
inflammation showing predominant infiltration of 
neutrophils 1271. In the present study, we detected an 
elevated level of 1CkDa group II phospholipase AZ ac- 
tivity at the inflamed sites in both experimental models, 
although the location of the phospholipase AZ remains 
to be identified. The results were consistent with 
previous observations that 1CkDa group II 
phospholipase A2 activity was detected in extra- 
articular tissues under various pathological conditions, 
which included experimental models of acute inflam- 
mation and human chronic inflammatory diseases 
W-161. These observations, together with a recent 
report that a potent regulator of inflammation, 
interleukin-1, induced transcription of the gene for 
14-kDa group II phospholipase A2 [28], suggest the 
possible involvement of the enzyme in a wide variety of 
pathogenic reactions. 
Purified rat group II phospholipase A2 exacerbated 
the adjuvant arthritis following injection in situ. The ef- 
fect was transient and induced at low doses of the en- 
zyme. The lowest amount of purified enzyme required 
for an appreciable ffect was 1 pg, which corresponds to 
about 20 units of the enzyme. Several investigators have 
previously pointed out the pathological activity of 
snake venom or pancreatic phospholipases AZ when ad- 
ministered exogenously. However, the amounts of these 
exocrine enzymes used were extraordinarily high 
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[ 17-201; Pruzanski et al. showed that inflammatory ef- 
fects of snake venom or pancreatic phospholipase AZ 
were induced by injection of 60 000 units of enzyme 
[17]. The amount of the enzyme we used in the present 
study was within the range of activity detected in the 
hind paw homogenates of rats with experimental in- 
flammation. Exogenously administered 14-kDa group 
II phospholipase A2 produced a dose-dependent effect. 
The endogenous 14-kDa group II phospholipase A2 
would in fact exacerbate adjuvant arthritis after secre- 
tion into the extracellular space under certain condi- 
tions. The precise mechanism by which 14-kDa group II 
phospholipase A2 exacerbates the inflammatory process 
is now under investigation. 
No appreciable inflammatory response was detected 
when 1CkDa group II phospholipase AZ was injected 
into the hind paw of normal rats. These findings were 
contradictory to previous reports of others. 
Vishwanath et al. have shown that phospholipase A2 
partially purified from human rheumatoid synovial 
fluid induced edema when injected into mouse foot 
pads [21]. Phospholipase A2 released from rabbit 
peritoneal exudate cells induced hyperemia subsequent 
to intradermal injection [19]. The discrepancy between 
the previous findings and the present data might be due 
to differences in sensitivity of the species employed. 
Alternatively, since only partially purified enzyme was 
used in previous studies, such preparations might have 
contained additional component(s) that affected the ac- 
tivity of the 1CkDa group II phospholipase AZ and 
potentiated the induction of some pathological 
responses. In fact, one such component, a bacterial 
permeability increasing protein, has already been 
characterized by Elsbach et al. [29]. 
It is noteworthy that no exacerbating effect was 
observed in rats with carrageenan-induced e ema when 
the animals were injected with 5 lg (100 units) of the 
phospholipase A?. The difference in the effects of ex- 
ogenous phospholipase A2 on adjuvant arthritis and 
carrageenan-induced ema cannot be explained at pre- 
sent. The major cellular component in carrageenan- 
induced edema is neutrophils, whereas that in adjuvant 
arthritis is mononuclear cells such as T lymphocytes or 
macrophages. Some cells accompanying with arthritis 
might therefore release factor(s) essential for expression 
of the pathological effects of mammalian 14-kDa group 
II phospholipase AL 
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